Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/68866
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610 |
Other Titles: | Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610 |
Author: | Okera, M. Bae, K. Bernstein, E. Cheng, L. Lawton, C. Wolkov, H. Pollack, A. Dicker, A. Sandler, H. Sweeney, C. |
Citation: | BJU International, 2011; 108(2B Sp Iss):E51-E58 |
Publisher: | Blackwell Publishing Ltd |
Issue Date: | 2011 |
ISSN: | 1464-4096 1464-410X |
Statement of Responsibility: | Meena Okera, Kyoungwha Bae, Eric Bernstein, Liang Cheng, Colleen Lawton, Harvey Wolkov, Alan Pollack, Adam Dicker, Howard Sandler and Christopher J. Sweeney |
Abstract: | Objective: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. Patients and Methods: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0–100%) and staining intensity (0–3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. Results: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P= 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. Conclusions: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted. |
Keywords: | Humans Prostatic Neoplasms NF-kappa B Receptors, CXCR4 Retrospective Studies Follow-Up Studies Aged Aged, 80 and over Middle Aged Male Randomized Controlled Trials as Topic Clinical Trials, Phase III as Topic |
Rights: | © 2010 The Authors. BJU International © 2010 BJU International |
DOI: | 10.1111/j.1464-410X.2010.09884.x |
Published version: | http://dx.doi.org/10.1111/j.1464-410x.2010.09884.x |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.